A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression

Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune System

(2022) Daniel Meraviglia-Crivelli et al.   Biomedicines

The origins and consequences of UPF1 variants in pancreatic adenosquamous carcinoma

(2021) Jacob T Polaski et al.   eLife

Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control

(2021) Claire Lhuillier et al.   JOURNAL OF CLINICAL INVESTIGATION

Biomarkers of Radiotherapy-Induced Immunogenic Cell Death

(2021) Rianne D. W. Vaes et al.   Cells

NMD inhibition by 5-azacytidine augments presentation of immunogenic frameshift-derived neoepitopes

(2021) Jonas P. Becker et al.   iScience

Deciphering the nonsense-mediated mRNA decay pathway to identify cancer cell vulnerabilities for effective cancer therapy

(2021) Roberta Bongiorno et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36).

(2020) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

Escape from nonsense-mediated decay associates with anti-tumor immunogenicity

(2020) Kevin Litchfield et al.   Nature Communications

Quality and quantity control of gene expression by nonsense-mediated mRNA decay

(2019) Tatsuaki Kurosaki et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

(2019) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic applications of AS1411 aptamer, an update review

(2019) Rezvan Yazdian-Robati et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy

(2019) Rik G. H. Lindeboom et al.   NATURE GENETICS

Inhibition of Upf2-Dependent Nonsense-Mediated Decay Leads to Behavioral and Neurophysiological Abnormalities by Activating the Immune Response

(2019) Jennifer L. Johnson et al.   NEURON

Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity

(2019) Greta Garrido et al.   Nature Communications

Evolution of the nonsense-mediated decay pathway is associated with decreased cytolytic immune infiltration

(2019) Boyang Zhao et al.   PLoS Computational Biology

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity

(2018) Brett Schrand et al.   Nature Communications

Targeting nonsense-mediated mRNA decay in colorectal cancers with microsatellite instability

(2018) A’dem Bokhari et al.   Oncogenesis

Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers

(2018) David Egg et al.   Frontiers in Immunology

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth

(2017) Giovanni Germano et al.   NATURE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biomarkers for immunotherapy in bladder cancer: a moving target

(2017) David H. Aggen et al.   Journal for ImmunoTherapy of Cancer

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

(2016) Neil H. Segal et al.   CLINICAL CANCER RESEARCH

The nonsense-mediated RNA decay pathway is disrupted in inflammatory myofibroblastic tumors

(2016) JingWei Lu et al.   JOURNAL OF CLINICAL INVESTIGATION

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts

(2015) Sebastien A. Burel et al.   NUCLEIC ACIDS RESEARCH

Attenuation of nonsense-mediated mRNA decay facilitates the response to chemotherapeutics

(2015) Maximilian W. Popp et al.   Nature Communications

5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion

(2014) M. Bhuvanagiri et al.   EMBO Molecular Medicine

TGF- : Duality of Function Between Tumor Prevention and Carcinogenesis

(2014) D. R. Principe et al.   JNCI-Journal of the National Cancer Institute

The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma

(2014) Chen Liu et al.   NATURE MEDICINE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

(2014) K. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

(2013) Jonathan E. Rosenberg et al.   INVESTIGATIONAL NEW DRUGS

Liver as a target for oligonucleotide therapeutics

(2013) Alfica Sehgal et al.   JOURNAL OF HEPATOLOGY

Smg1 haploinsufficiency predisposes to tumor formation and inflammation

(2013) Tara L. Roberts et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination

(2013) Adam J Litterman et al.   OncoImmunology

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer

(2009) Paula J. Bates et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY